Bayer HealthCare Pharmaceuticals Inc. (Bayer)

Oncology Corporate Profile

HQ Location

6 Westbelt
Wayne, NJ 7470

Company Description

Bayer combines the global activities of the divisions Animal Health, Bayer Schering Pharma, Consumer Care and Medical Care. More than 50,000 people are employed by Bayer HealthCare worldwide. Bayer's aim is to discover and manufacture innovative products that will improve human and animal health worldwide.


Brand Generic Indication
Nexavar®sorafenibNexavar® is a kinase inhibitor indicated for the treatment of: unresectable hepatocellular carcinoma; advanced renal cell carcinoma; locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.
Stivarga®regorafenibStivarga® (regorafenib) is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild-type, an anti-EGFR therapy. Stivarga® is indicated for the treatment of patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.
Xofigo®radium Ra 223 dichlorideXofigo® (radium Ra 223 dichloride) injection is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.

View additional information on commercial products here »

  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
ODM-201androgen receptor antagonistCastration-resistant Prostate cancerIII
radium 223 dichlorideradiotherapeuticColorectal cancerIII
regorafenibanti-VEGF therapyColorectal cancerIII
regorafenibanti-VEGF therapyHepatocellular carcinoma (HCC)III
ODM-201androgen receptor antagonistHormone-sensitive Prostate cancerIII
copanlisibPI3K inhibitorNon-Hodgkin's Lymphoma (NHL)III
bonefosbisphosphonatePrevention of bone metastasesIII
Nexavar® / sorafenibmulti-targeted protein kinase inhibitor1st line metastatic Breast cancerIII
Nexavar® / sorafenibmulti-targeted protein kinase inhibitor1st line metastatic Non Small Cell Lung Cancer (NSCLC)III
Nexavar® / sorafenibmulti-targeted protein kinase inhibitorAdjuvant Hepatocellular carcinoma (HCC)III
Nexavar® / sorafenibmulti-targeted protein kinase inhibitorMelanomaIII
Xofigo® / radium Ra 223 dichloride (+ abiraterone acetate and prednisone)radiotherapeuticChemotherapy-naive patients with bone predominant metastatic castration-resistant prostate cancer (mCRPC)III
lonaprisan / BAY86-5044progesterone receptor antagonist2nd line metastatic Breast CancerII
radium 223 dichlorideradiotherapeuticBone metastasesII
radium 223 dichlorideradiotherapeuticBreast cancerII
copanlisibPI3K inhibitorDiffuse Large B-Cell Lymphoma (DLBCL)II
refametinib / BAY 86-9766MEK inhibitorHepatocellular carcinoma (HCC)II
anetumab ravtansineantibody drug conjugate (ADC)MesotheliomaII
copanlisibPI3K inhibitorNon-Hodgkin's Lymphoma (NHL)II
radium 223 dichlorideradiotherapeuticVarious cancer typesII
regorafenibanti-VEGF therapyVarious cancer typesII
regorafenibanti-VEGF therapyVarious cancer typesII
Nexavar® / sorafenib (+ capecitabine)multi-targeted protein kinase inhibitor2nd line metastatic Breast cancerII
Nexavar® / sorafenibmulti-targeted protein kinase inhibitor2nd line metastatic Non Small Cell Lung Cancer (NSCLC)II
Nexavar® / sorafenibmulti-targeted protein kinase inhibitorColorectal cancerII
Nexavar® / sorafenibmulti-targeted protein kinase inhibitorOvarian cancerII
Stivarga® / regorafenibanti-VEGF therapyRenal cell carcinoma (RCC)II
L19-TNFalphaimmunotherapyColorectal cancerI
L19-Interleukin 2immunotherapyMelanomaI
L19-Interleukin 2immunotherapyPancreatic cancerI

View additional information on product candidates here »


Recent News Headlines

Bayer Applies For Regorafenib Authorization To Treat Liver Cancer

11/7/2016 05:19 pm

(Reuters) Nov 7, 2016 - German drugmaker Bayer on Monday said it submitted an application to have its cancer drug Regorafenib approved for the second-line treatment of liver cancer patients following successful clinical trials.

Bayer Submits Supplemental New Drug Application for Stivarga® (regorafenib) for Advanced Liver Cancer

11/7/2016 12:57 pm

(Bayer) Nov 7, 2016 - Bayer today announced that a supplemental New Drug Application (sNDA) for Stivarga® (regorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the second-line systemic treatment of patients with unresectable hepatocellular carcinoma (uHCC).

Bayer’s Euphoria Around New Cancer Medicine Meets Skepticism

10/18/2016 12:10 pm

(Bloomberg) Oct 18, 2016 - Bayer AG’s promises of soaring sales for its experimental pipeline of drugs -- hinging in large part on an unproven treatment for an uncommon cancer -- are being met with skepticism.

NICE Rejects Lilly's Portrazza, but Backs Bayer's Xofigo and Amgen's Imlygic

9/30/2016 04:41 pm

(PharmaTimes [UK]) Sept 30, 2016 - Patients with lung cancer will not be able to access Eli Lilly's Portrazza on the National Health Service in England and Wales, after a final rejection from the National Institute for Health and Care Excellence.

U.S. FDA Approves Bayer Contraceptive Device Kyleena

9/19/2016 04:49 pm

(Reuters) Sept 19, 2016 - The U.S. Food and Drug Administration approved Bayer AG's hormonal contraceptive device, Kyleena, to prevent pregnancy for up to five years, the German company said on Monday.

NICE Rejects Bayer's Nexavar for Liver Cancer

8/19/2016 12:04 pm

(PharmaTimes [UK]) Aug 19, 2016 - Bayer's Nexavar is the latest medicine currently available through the Cancer Drugs Fund that has failed to meet cost-effectiveness standards set by the National Institute for Health and Care Excellence.

Judge Rules Against Nearly 1,300 Lawsuits Over Bayer's Mirena IUD

7/29/2016 04:19 pm

(Reuters) July 28, 2016 - A New York federal judge has ruled in favor of Bayer AG against nearly 1,300 lawsuits filed by women who say they suffered internal injuries from the company's Mirena intra-uterine contraceptive device.

Bayer’s Regorafenib Significantly Improves Overall Survival in Patients with Unresectable Liver Cancer

6/28/2016 05:49 pm

( June 28, 2016 - Initial results from Phase III trial RESORCE to be presented as Late-Breaking Abstract in oral abstract session at WCGC; median overall survival was 10.6 months for patients treated with regorafenib plus best supportive care versus 7.8 months in the group treated with placebo plus best supportive care.

Pfizer Bolsters China Presence With $350 Million Plant

6/28/2016 12:02 pm

(Bloomberg) June 27, 2016 - Pfizer Inc. will invest $350 million in eastern China on a plant for biotechnology drugs, bolstering its presence in the world’s second largest pharmaceutical market despite slowing economic growth in the country and rising pressure on prices for medicines.

End-Of-Life Care Better For Patients With Cancer, Dementia: Study Finds

6/27/2016 12:04 pm

(Kaiser Health News) June 27, 2016 - A new study offers surprising findings about end-of-life care — specifically, physicians tend to be more likely to accommodate the advanced-care wishes of patients with cancer or dementia than renal disease, congestive heart failure, pulmonary disease or frailty.

Bubbly Drinks Inspire More Effective Cancer Treatment

6/8/2016 11:03 am

(Cancer Research UK) June 8, 2016 - Cancer Research UK scientists are developing a bubbly drink packed with oxygen microbubbles to make treatments more potent for hard to treat tumours like pancreatic cancer.

TAPUR Study Achieves Milestones: Forty-Nine Patients Consent to Participate, Bayer and Merck Sign on as Drug Providers, and Thirty-Seven Sites Are Participating Twelve Weeks Post-Launch

6/6/2016 07:32 pm

(ASCO) June 6, 2016 - The American Society of Clinical Oncology (ASCO) announced today that Bayer and Merck are the most recent companies to sign on to provide study drugs at no cost to patients enrolled in the Targeted Agent and Profiling Utilization Registry (TAPUR) study, joining six other companies in ASCO’s first-ever clinical trial.

Bayer and Orion Expand Clinical Development Program for BAY-1841788 (ODM-201) in Prostate Cancer

6/3/2016 06:21 pm

(StreetInsider) June 3, 2016 - Phase III study to be initiated in metastatic hormone-sensitive prostate cancer assessing the androgen-receptor antagonist in combination with standard androgen deprivation therapy and the chemotherapy docetaxel; start of patient enrollment expected towards the end of 2016.

Scientists Identify New Drivers of Rare Cancer Type

5/31/2016 11:02 am

(University of Würzburg [Germany]) May 30, 2016 - Cancer researchers have identified new genetic drivers of adrenal cancer by performing a comprehensive genomic analysis as part of the "Cancer Genome Atlas Research Network.”

Monsanto Poised to Reject $62 Billion Bayer Takeover Bid

5/24/2016 05:35 pm

(Bloomberg) May 24, 2016 - Monsanto Co. is poised to reject a $62 billion takeover offer from Germany’s Bayer AG as too low, according to people with knowledge of the matter, potentially derailing a proposed deal to create the world’s biggest supplier of farm chemicals and seeds.

Novocure Enrolls Last Patient in PANOVA Trial of Tumor Treating Fields Plus Chemotherapy in Advanced Pancreatic Cancer

5/24/2016 11:01 am

(Morningstar) May 23, 2016 - Novocure announced today that the last patient has been enrolled in the PANOVA trial, a phase 2 pilot trial testing Tumor Treating Fields (TTFields) plus chemotherapy in 40 patients with advanced pancreatic cancer. The final data collection date will be six months after the last patient in.

Bayer Offers $62 Billion To Buy Monsanto

5/23/2016 05:11 pm

(Washington Post) May 23, 2016 - Bayer said on Monday said that it has offered to buy Monsanto for $62 billion in cash, potentially creating a giant agrochemicals company that would span genetically modified seeds and pesticides to antibiotics.

Bayer to Showcase Latest Oncology Research at ASCO 2016

5/19/2016 05:30 pm

(Yahoo! Finance) May 18, 2016 - Scientific presence features latest data on radium-223 dichloride, regorafenib, sorafenib, and pipeline research as well as findings from largest global survey in advanced prostate cancer.

Castle Biosciences Announces New Clinical Data Presentations at ASCO 2016 Underscoring the Accuracy and Clinical Utility of Gene Expression Profile Test for Cutaneous Melanoma

5/19/2016 12:03 pm

(Yahoo! Finance) May 19, 2016 - Castle Biosciences, Inc. today announced that several abstracts on the Company’s gene expression profile (GEP) tests for cancer were accepted for poster presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from June 3-7.

Bayer Says Its Drug Extends Lives Of Liver Cancer Patients

5/4/2016 06:09 pm

(Reuters) May 4, 2016 - Bayer AG said on Thursday its Regorafenib cancer treatment drug helped extend the lives of liver cancer sufferers according to the results of a Phase III clinical trial.

Via Oncology Launches Expanded Support for CMMI OCM Practices

4/26/2016 10:04 am

(PRWEB) Apr 26, 2016 - Via Pathways and Via Portal have been expanded to support key components for success in the Oncology Care Model from the Centers for Medicare and Medicaid Innovation.

Compugen’s Cancer Immunotherapy Partnership with Bayer Achieves 1st Preclinical Milestone

4/20/2016 05:19 pm

(Immuno-Oncology News) Apr 20, 2016 - Compugen announced it has achieved its first preclinical milestone with its immune checkpoint target candidate CGEN-15022, a result of its cancer immunotherapy collaboration with Bayer.

US Approves Bayer's Kovaltry for Haemophilia A

3/17/2016 05:09 pm

(PharmaTimes [UK]) Mar 17, 2016 - US regulators have issued a green light for Bayer’s Kovaltry for the treatment of haemophilia A in children and adults.

Neurofeedback Reduces Pain, Increases Quality Of Life For Cancer Patients Suffering From Chemotherapy-Induced Neuropathy

3/14/2016 11:03 am

(MD Anderson) Mar 11, 2016 - A new study from The University of Texas MD Anderson Cancer Center evaluating the use of neurofeedback found a decrease in the experience of chronic pain and increase quality of life in patients with neuropathic pain.

Bayer Joins Forces with Advocacy Organizations to Support Disease Education During Colon Cancer Awareness Month

3/1/2016 05:49 pm

(Bayer) Mar 1, 2016 - To mark Colorectal Cancer Awareness Month, Bayer unites with patient advocacy organizations Colon Cancer Alliance and Fight Colorectal Cancer to raise greater awareness about the disease and its progression.

FDA Asks For More Studies On Bayer's Essure Contraceptive Implant

2/29/2016 06:27 pm

( Feb 29, 2016 - The U.S. Food and Drug Administration said on Monday it had asked German drugmaker Bayer AG to conduct further studies on its implantable sterilization device, Essure, following thousands of complaints and calls for its withdrawal.

Bayer Names Werner Baumann to Succeed Marijn Dekkers as CEO

2/24/2016 06:12 pm

(Bloomberg) Feb 24, 2016 - Bayer AG, Germany’s second-largest company by market value, named chief strategy and portfolio officer Werner Baumann as its next chief executive officer, ending almost two years of speculation on Marijn Dekkers’s successor.

Tx Trio Ups PFS in Heavily Pretreated Myeloma

2/17/2016 11:05 am

(MedPage Today) Feb 16, 2016 - A combination of panobinostat (Farydak), bortezomib (Velcade), and dexamethasone (PAN-BTZ-Dex) achieved the longest median progression-free survival in relapsed and refractory multiple myeloma patients heavily pretreated with at least two regimens, including bortezomib and immunomodulatory drugs (ImiDs).

OncoGenex Announces Reduction in Force to Extend Cash Runway and Align Operations with Clinical Development Priorities

2/5/2016 12:03 pm

(Yahoo! Finance) Feb 4, 2016 - OncoGenex Pharmaceuticals, Inc. announced today that it is implementing a plan to reduce operating expenses, including a workforce reduction of approximately 27%.

ImmunoGen Earns Milestone with Bayer's Initiation of a Phase 2 Clinical Study Designed to Support Anetumab Ravtansine Registration

1/26/2016 05:45 pm

(ImmunoGen) Jan 26, 2016 - ImmunoGen, Inc. today announced the Company earned a milestone payment with Bayer's initiation of a global Phase 2 clinical study designed to support registration of anetumab ravtansine (BAY 94-9343).

Affimed Enters into Collaboration with Merck to Evaluate AFM13 in Combination with KEYTRUDA(R) (pembrolizumab) for Patients with Hodgkin Lymphoma

1/25/2016 11:03 am

(CNNMoney) Jan 25, 2016 - Affimed N.V., a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that it has entered into a clinical research collaboration in immuno-oncology with Merck, known as MSD outside the United States and Canada.

‘Therapy Comfort Care Kits’ Now Delivered To All Cancer Patients at BioPlus Specialty Pharmacy

1/20/2016 12:01 pm

(PRWEB) Jan 19, 2016 - Support items for easing cancer treatment side effects sent to oncology patients in a new program at BioPlus Specialty Pharmacy.

Bayer in Venture With Gene-Editing Startup

12/21/2015 06:04 pm

(Wall Street Journal) Dec 20, 2015 - German pharmaceutical group Bayer AG will establish a joint venture with gene-editing startup Crispr Therapeutics AG and invest at least $300 million in the partnership in five years, in an effort to develop new medicines based on the emerging technology, the companies said.

American Association for Cancer Research and Bayer Form Partnership on Grant Opportunities in Cancer Research

12/21/2015 06:03 pm

(AACR) Dec 18, 2015 - The American Association for Cancer Research (AACR) and Bayer are pleased to announce the 2016 AACR-Bayer Innovation and Discovery Grants program for meritorious projects that examine novel targets and biomarkers in oncology research.

Compugen Achieves Third Preclinical Milestone In Cancer Immunotherapy Collaboration With Bayer

12/11/2015 06:45 pm

(TheStreet) Dec 11, 2015 - Compugen Ltd., a leading predictive drug discovery company, announced today that it has achieved the third preclinical milestone pursuant to its cancer immunotherapy collaboration with Bayer HealthCare (Bayer).

Cancer Drug Quest Drives Bayer's Pipeline Investment

12/11/2015 06:45 pm

(Bloomberg) Dec 11, 2015 - Bayer AG is packing more cancer drugs into its pipeline to gain a bigger share of the almost $100 billion global market for such treatments.

NICE OK's Restricted Use of Bayer's Prostate Cancer Drug

11/19/2015 06:31 pm

(PharmaTimes [UK]) Nov 19, 2015 - The National Institute for Health and Care Excellence will this morning issue a Final Appraisal Determination recommending Bayer's Xofigo for National Health Service use to treat certain patients with prostate cancer, but only in the post-chemo setting.

N-of-One Selected by Spectrum Health to Provide Clinical Interpretation for 50-Gene Hot-Spot Solid Tumor Panel

8/18/2015 12:01 pm

(Yahoo! Finance) Aug 18, 2015 - N-of-One, Inc., the leader in clinical interpretation for precision medicine in oncology, today announced that it has signed an agreement with Spectrum Health to provide clinical interpretation for all cases sequenced on Spectrum Health’s 50-gene hot-spot solid tumor panel.

World's First Malaria Vaccine Wins CHMP Favour

7/24/2015 11:04 am

(PharmaTimes [UK]) July 24, 2015 - GlaxoSmithKline's malaria candidate vaccine Mosquirix, which has been nearly 30 years in the making, has won a positive opinion from European regulators for the prevention of malaria in young children in sub-Saharan Africa.

Study Explores Protein's Role in Inflammation-Associated Cancer

7/24/2015 11:01 am

(VICC) July 23, 2015 - A protein that transports the micronutrient selenium and has antioxidant functions may protect against colitis-associated carcinoma — colon cancer that develops in patients with inflammatory bowel disease, according to a new Vanderbilt-led study.

Cancer Specialist Testifies In Fata Medical Fraud Case

7/8/2015 12:00 pm

(The Detroit News) July 8, 2015 - Another cancer specialist is testifying Wednesday in the sentencing phase of the federal criminal case against local oncologist Dr. Farid Fata, who is accused of bilking Medicare out of millions and prescribing unnecessary chemotherapy to patients who didn't have cancer.

More Men With Prostate Cancer Are Opting For Surveillance

7/8/2015 11:03 am

(Reuters Health) July 7, 2015 - Men with early-stage prostate cancer are increasingly opting for regular monitoring and holding off on treatment unless the disease progresses, a new study suggests.

MorphoSys Presents First Safety, Pharmacokinetic and Efficacy Data for MOR202 in Multiple Myeloma at ASCO Meeting

5/31/2015 07:00 pm

(StreetInsider) May 31, 2015 - MorphoSys AG today published first safety and efficacy data on its proprietary drug candidate MOR202. The data are from a phase 1/2a study in 42 heavily pretreated patients with relapsed/refractory multiple myeloma.

New Data from IMAGE 1 Show Improved Survival in Metastatic Pancreatic Cancer in Patients Receiving IMM-101

5/15/2015 12:02 pm

(SYS-CON Media) May 14, 2015 - Immodulon Therapeutics today announced updated results of long-term survival from IMAGE 1, a randomized, controlled, open-label, Phase II clinical trial comparing the combination of IMM-101 and gemcitabine (IMM-101 treated) versus gemcitabine alone (control) as first-line treatment for advanced pancreatic cancer.

10 Important Checkpoint Inhibitor Cancer Drug Abstracts from ASCO '15

5/14/2015 01:03 pm

(The Street) May 13, 2015 - For the past few years, the American Society of Clinical Oncology (ASCO) annual meeting has been dominated by cancer immunotherapy -- drugs which activate the body's own immune system to identify and kill cancer cells.

Merck KGaA, Threshold Win Fast Track for Pancreatic Cancer Drug

5/12/2015 11:01 am

(Fox May 12, 2015 - Germany's Merck KGaA said that experimental cancer drug evofosfamide, which it is jointly developing with Threshold Pharmaceuticals, won fast track status for the treatment of advanced pancreatic cancer from the U.S. Food and Drug Administration.

Seven New Drugs OK'd for NHS Scotland

4/14/2015 12:01 pm

(PharmaTimes [UK]) Apr 13, 2015 - Seven new medicines have been accepted for use by the National Health Service in Scotland, including therapies for leukaemia, lung cancer and multiple sclerosis.

Penn Vet Team Points to New Colon Cancer Culprit

3/16/2015 11:01 am

(Penn News) Mar 16, 2015 - A team of researchers from the University of Pennsylvania has found evidence of a new culprit in colon cancer, a protein called MSI2.

A True Fountain-Of-Youth Drug Combo?

3/16/2015 11:01 am

(Forbes) Mar 16, 2015 - A new study shows dramatic anti-aging effects using a combination of two compounds: a common supplement and a cancer chemotherapeutic. If the results in mice carry over to humans, this could transform our treatment of age-related diseases.

Older, White Males with Advanced Bladder Cancer at High Risk for Suicide

3/4/2015 12:00 pm

(Georgia Regents University & Health System) Mar 4, 2015 - Older, single white males with advanced bladder cancer have the highest suicide risk among those with other cancers of the male genitals and urinary system, researchers report.